Hong Kong to welcome world-leading siRNA company as Ribo launches its IPO
The small nucleic acid drugs developer has positioned itself as a leader in siRNA therapeutics, boasting one of the world’s largest pipelines of drugs using the technology Key Takeaways: Ribo…
RELATED ARTICLES
-
BRIEF: Leading RNA drug developer Ribo passes Hong Kong listing hearing, kicking off IPO
- Armed with AstraZeneca deal, Eccogene files for Hong Kong IPO
- Obesity drug maker Sciwind targets IPO, with heavyweight backers
- Ming Yu seeks a share of the drug sector limelight
-
Precision cancer drugs show promise for Kelun-Biotech
6990.HK
- Genuine Biotech takes third shot at IPO as financial pressures mount
-
Hengrui Pharma targets obesity drug launch after test success
1278.HK600276.SHG
